Teriparatide (recombinant human parathyroid hormone [1-34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study.

Rastogi A, Hajela A, Prakash M, Khandelwal N, Kumar R, Bhattacharya A, Mittal BR, Bhansali A, Armstrong DG

Journal of diabetes13 Feb 2019Cited by 17 (Europe PMC)

PMID30632290DOI10.1111/1753-0407.12902PepBankPUB-30632290

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with diabetic chronic Charcot neuroarthropathy, teriparatide increased foot SUVmax more than placebo.
In plain wordsIn people with diabetic Charcot foot, teriparatide increased foot bone SUVmax more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFoot SUVmax
Study
n = 20
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
SUVmax
30.6 g/ml
teriparatide group, baseline
SUVmax
37.7 g/ml
teriparatide group, 12 months
SUVmax
27.6 g/ml
placebo group, baseline
SUVmax
22.9 g/ml
placebo group, 12 months
Estimated treatment difference in SUVmax
11.9 g/ml
teriparatide vs placebo
Source sentences
Summary
The estimated treatment difference (ETD) was 11.9 ± 4.3 (95% CI 2.9, 20.8; P = 0.012).
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 months, SUV_max increased from 30.6 ± 14.7 to 37.7 ± 18.0 (P = 0.044) in the teriparatide group, but decreased from 27.6 ± 12.2 to 22.9 ± 10.4 with placebo (P = 0.148).
Summary · context
The primary outcome measure was change in SUV_max g/ml.
Summary · context
People with diabetes and chronic CN were randomized to receive either 20 μg teriparatide or placebo subcutaneous daily for 12 months.
Report a problemFND-3063229001
02HumanRandomized controlled trialMechanism
In people with chronic Charcot neuroarthropathy, teriparatide increased P1NP compared with placebo.
In plain wordsIn people with Charcot foot, teriparatide increased the bone formation marker P1NP compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseP1NP
Study
n = 20
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
P1NP change
19.8 ng/mL
teriparatide group
P1NP change
−5.1 ng/mL
placebo group
Estimated treatment difference in P1NP
24.8 ng/mL
teriparatide vs placebo
Source sentences
Summary
Similarly, P1NP increased with teriparatide (19.8 ± 5.5; P = 0.006) but decreased with placebo (-5.1 ± 3.8 ng/mL; P = 0.219); ETD was 24.8 ± 6.6 (95% CI 10.8, 38.8; P < 0.001) and CTX increased in both the teriparatide and placebo groups.
1 context sentence(design, population, supporting numbers)
Summary · context
People with diabetes and chronic CN were randomized to receive either 20 μg teriparatide or placebo subcutaneous daily for 12 months.
Report a problemFND-3063229002
03HumanRandomized controlled trialEfficacy outcome
In people with chronic Charcot neuroarthropathy, foot BMD did not differ significantly between teriparatide and placebo.
In plain wordsIn people with Charcot foot, foot bone density did not differ significantly between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFoot BMD
Study
n = 20
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Foot BMD change
0.06 g/cm2
teriparatide group
Foot BMD change
−0.06 g/cm2
placebo group
Source sentences
Summary
Foot BMD increased by 0.06 ± 0.04 g/cm² (P = 0.192) with teriparatide, but decreased by -0.06 ± 0.08 g/cm² with placebo (P = 0.488; intergroup comparison, P = 0.096).
1 context sentence(design, population, supporting numbers)
Summary · context
People with diabetes and chronic CN were randomized to receive either 20 μg teriparatide or placebo subcutaneous daily for 12 months.
Report a problemFND-3063229004

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism
In people with chronic Charcot neuroarthropathy, CTX increased in both teriparatide and placebo groups.
In plain wordsIn people with Charcot foot, CTX increased in both the teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCTX
Study
n = 20
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
and CTX increased in both the teriparatide and placebo groups.
1 context sentence(design, population, supporting numbers)
Summary · context
People with diabetes and chronic CN were randomized to receive either 20 μg teriparatide or placebo subcutaneous daily for 12 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3063229003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.